Automated Breast Ultrasound Systems Market
Number of pages: 100 | Report Format: PDF | Published date: March 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.06 billion |
|
Revenue Forecast in 2031 |
US$ 10.11 billion |
|
CAGR |
14.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global automated breast ultrasound systems market was valued at US$ 3.06 billion in 2022 and is expected to register a revenue CAGR of 14.2% to reach US$ 10.11 billion by 2031.
Automated Breast Ultrasound Systems Market Fundamentals
Automated breast ultrasound (ABUS) is a type of ultrasound that is increasingly being utilized as a complement in the examination of patients with thick glandular breasts. Individuals with dense breasts are more likely to get breast cancer than people with fatty breasts. Additionally, mammography has limited sensitivity in detecting breast tumors in this group of patients, especially if it is not linked to architectural distortion or calcifications. The Food and Drug Administration (FDA) approved ABUS in 2012 as an additional screening tool for women with heterogeneously and very dense breasts. Approval became attainable following the crucial clinical retrospective multi-reader research conducted by U-Systems. The study comprised 164 patients, 133 non-tumors, and 31 cancers confirmed by biopsy. A total of 17 radiologists assessed the mammograms separately first, then the combined mammography and ABUS. Since non-physician individuals acquire the images, ABUS offers various advantages, including minimal operator dependency and good repeatability. Storing images on a separate station enables multiplanar reconstructions and allows for double-reading and objective comparison with earlier tests.
The breasts are movable pendulous organs of various sizes, shapes, and densities. The receptor plate is not intended to accommodate all breasts, and outlying regions may be neglected. To cover the whole breast, technologists choose the best configuration for each patient according to breast size, and three to five views of each breast are obtained. An average exam includes three automated scans of each breast in the anterior-posterior, medial, and lateral perspectives. Further views of the superior and inferior sections of the breasts are necessary in the case of large breasts.
Recently, CAD (computer-aided detection) software created for an ABUS (QVCADTM, QView Medical, Los Altos, CA, USA) received FDA approval and showed promising performance in breast cancer diagnosis. A retrospective observer performance assessment improved mean interpretation time by 33% on average among 18 radiologists without affecting diagnostic accuracy. CAD was examined uniformly; each reader interpreted each case twice, once without and once with the CAD system, separated by 4 weeks.
[76767]
Automated Breast Ultrasound Systems Market Dynamics
Continuous technical improvements in breast cancer detection systems drive the global automated breast ultrasound systems market. The industry is developing various innovative technologies to improve cancer screening in patients with dense breast cancer, boosting breast cancer detection’s efficacy. Moreover, advances in ABUS are projected to overcome shortcomings in traditional systems. Technological advancements are predicted to increase demand for more advanced cancer imaging, propelling the automated breast ultrasound systems market forward.
A key element driving revenue growth in the global automated breast ultrasound systems market is the rapidly increasing number of breast cancer patients globally. Additional significant variables contributing to the increased prevalence of breast cancer include hormone replacement medication, obesity, decreased childbearing, and age-related difficulties. This drives the need for screening and more precise detection due to the dangers of subsequent complications.
As the global occurrence of cancer rises, corporations release technologically improved products to increase their market position. For example, in October 2018, GE Healthcare introduced Invenia Automated Breast Ultrasonography (ABUS) 2.0 in the United States. This gadget was developed primarily to detect cancer in thick tissues overlaying the chest. These factors are expected to boost the market over the projected period. In another instance, according to the American Cancer Society, there will be approximately 287,840 new cases of invasive breast cancer in women in 2022, 51,400 new cases of ductal carcinoma in situ, and 43,250 new cases of breast cancer-related deaths in women.
Breast cancer is more common in middle-aged and older women. Breast cancer is often diagnosed around the age of 62. As a result, the average age at which breast cancer is discovered in women is 62 years or less. Breast cancer diagnoses in women under the age of 45 are extremely rare. Its increased incidence rate is attributable to increased sedentary behavior, obesity, and changes in living patterns. Also, rising alcohol intake is likely to raise the risk of this kind of cancer. Women who drink three alcoholic drinks every week increase their risk by 7%-12%. The danger might rise by another 10% per additional unit of alcohol per day.
Automated Breast Ultrasound Systems Market Ecosystem
The global automated breast ultrasound systems market has been analyzed from three perspectives: product, end user, and region.
Automated Breast Ultrasound Systems Market by Product
[98765]
Based on product, the automated breast ultrasound systems market has been segmented into automated breast ultrasound system systems (ABUS) and breast volume scanners (ABVS).
The automated breast ultrasound systems (ABUS) segment will likely dominate the market during the forecast period. The automated breast ultrasound system market is expanding due to the availability of various products, technical developments, and user-friendly device features. Invenia ABUS 2.0 by GE Healthcare, SOFIA 3D breast ultrasound system by Hitachi Ltd., EPIQ ultrasound system by Koninklijke Philips N.V., and ACUSON S2000 by Siemens Healthineers AG are some of the products supplied by significant players.
The automated breast volume scanners (ABVS) segment is predicted to increase steadily throughout the projection period. The technology detects cancers, lesions, and other abnormalities in the tissues that cover the chest. Nevertheless, these devices are often operator reliant, with a low capacity to identify accurate findings on the first try, which is projected to limit market expansion. Moreover, increased demand for technologically improved devices for better disease diagnostics is expected to hamper segment expansion.
Automated Breast Ultrasound Systems Market by End User
Based on end user, the automated breast ultrasound systems market has been segmented into hospitals, diagnostics imaging laboratories, and clinics.
The hospitals segment is expected to dominate the market during the forecast period. This is due to an increase in the number of instances of breast cancer worldwide, as well as the introduction of technologically sophisticated devices by important manufacturers. Furthermore, measures conducted by the government and non-profit organizations to promote awareness about the condition and its treatment technique are likely to enhance market revenue growth throughout the forecast period.
Automated Breast Ultrasound Systems Market by Region
Based on region, the automated breast ultrasound systems market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest share owing to the increasing prevalence of cancer and the presence of key players in the region. Furthermore, even women with no history of cancer are advised by US screening standards to begin obtaining mammograms when they reach the age of 40 or 50. They are also advised to continue once every one or two years, which is done regularly until age 75. This critical aspect is predicted to boost market expansion in the region in the future. Additionally, the prevalence of breast cancer is particularly high in North American countries.
The Asia Pacific market is predicted to expand the most during the forecast period, owing to increased awareness and treatment of this form of cancer among women in the region. Raising awareness, particularly in certain emerging nations, is leading to an increase in women seeking screening and diagnosis at camps and centers. Several groups in the region run breast cancer awareness campaigns and campaigns to generate cash for research and development of more technologically advanced treatment methods.
Automated Breast Ultrasound Systems Market Competitive Landscape
The prominent participants in the global automated breast ultrasound systems market include:
Automated Breast Ultrasound Systems Market Strategic Developments
Automated breast ultrasound (ABUS) is a type of ultrasound that is increasingly being utilized as a complement in the examination of patients with thick glandular breasts. Individuals with dense breasts are more likely to get breast cancer than people with fatty breasts.
Asia Pacific is the key revenue growth region in the global automated breast ultrasound systems market.
The rising demand for ABUS systems and the surging volume of breast cancer patients are propelling revenue growth in the global market.
The automated breast ultrasound system segment leads the global automated breast ultrasound systems market.
The automated breast ultrasound systems market is expected to register a revenue CAGR of 14.2% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain